Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Andreas Ohm

Helmut Luchtenberg

Peter Serno

Roland Rupp

Manfred Bucheler

Alfons Grunenberg

Josef Schmoll

Rainer Bellinghausen

Jan-Olav Henck

Takaaki Nishioka

Hanna Tinel

Venkata-Rangarao Kanikanti

Wolfgang Opitz

Peter Kurka

Alexander Kuhl

Klaus Benke

Axel Wollenschlager

Adrian Funke

Joachim Hütter

Erich Brendel

Hans-Martin Siefert

Eduard Porges

Ulrich Tenter

Haruo Kanasaki

Kenji Kuratani

Eimer Vollers

Dieter Zimmer

Frank Bröcker

Wolfgang Barth

Richard-Josef Bauer

Wolfgang Muck

Thomas Volkmer

Heinrich Feltkamp

Shinji Maegata

Dennis Kvesic

Elmer Vollers

Gerd Toppel

Elmer Volters

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic

The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.

Medicaments containing vardenafil hydrochloride trihydrate

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine and/or nisoldipine and at least one angiotensin II antagonist, characterized in that the active ingredient combination undergoes controlled (modified) release in the body, and to processes for the production thereof, to the use thereof as pharmaceuticals, to the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for manufacturing a pharmaceutical for the prophylaxis, secondary prophylaxis and/or treatment of disorders.

Pharmaceutical dosage forms comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin II antagonist

The present invention relates to imidazotriazinone-containing compositions for nasal administration which, besides the cGMP PDE inhibitor, contain a small amount of a local anaesthetic.

Imidazotriazinone-containing compositions for nasal administration

The invention relates to pharmaceutical preparations having controlled release of active compound and to processes for their preparation, in particular for poorly soluble active compounds having problematic bioavailability.

Pharmaceutical preparations having controlled release of active compound

This invention provides a long-lasting release solid nifedipine preparation which exhibits clinically sufficient effect when administered once per day. A press coated tablet whose core and shell each contains nifedipine, the dissolution rate of nifedipine from said tablet being (a) in the dissolution test using a sinker according to method 2 of the dissolution test method as prescribed by the Pharmacopoeia of Japan, after 2 hours 10-40% after 4 hours 30-65% after 6 hours at least 55%, and (b) in the dissolution test according to the disintegration test method as prescribed by the Pharmacopoeia of Japan, after 3 hours 20-45% after 4 hours 30-65%.

Long-lasting release nifedipine preparation

Controlled release medicament pellets comprising

Medicaments having controlled release of the active compound

A solid medicament preparation having long-lasting action containing a sparingly soluble dihydropyridine active compound of the Formula (I) ##STR1## the preparation having a core-coating construction, the core containing at least one of the above mentioned dihydropyridines in slow-release form, the inner-most coating situated around the core contains no active compound and only dissolves slowly and adjacent to the inner-most coating a rapid release initial dose of the active compound mixed with a polymer.

DHP delayed release preparation

A pharmaceutical formulation tablet with a long-lasting action for 1 to 2 daily doses having a diameter between about 0.5 and 15 mm and comprising

Dihydropyridine depot formulation

The invention relates to solid pharmaceutical preparations which have a long-lasting action and are for dihydropyridines in the form of a press coated tablet, and a process for their preparation.

Press coated DHP tablets

Growing community of inventors

Neuss, Germany

Andreas Ohm